Product Name: EphB2-BKCD
Product Number: AB-NK267-1
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Ephrin type-B receptor 2 protein-tyrosine kinase
Target Alias: CEK5; DRT; Eph receptor B2; Eph3; Eph-3; EphB2; Ephrin type-B receptor 2; EphT3; Hek5; Tyro5; MGC87492; ENSG00000133216
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK267-1
Antibody Target Type: Pan-specific
Protein UniProt: P29323
Protein SigNET: P29323
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human EphB2 sequence peptide Cat. No.: PE-01BCU95
Target Alias: CEK5; DRT; Eph receptor B2; Eph3; Eph-3; EphB2; Ephrin type-B receptor 2; EphT3; Hek5; Tyro5; MGC87492; ENSG00000133216
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK267-1
Antibody Target Type: Pan-specific
Protein UniProt: P29323
Protein SigNET: P29323
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human EphB2 sequence peptide Cat. No.: PE-01BCU95
Antibody Immunogen Sequence: PNEAVREFAKEIDISC
Antibody Immunogen Description: Corresponds to amino acid residues P605 to C620; Just before catalytic domain; Note the seqence is identical in EphB1, EphB2, EphB3 an EphB4
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Immunogen Description: Corresponds to amino acid residues P605 to C620; Just before catalytic domain; Note the seqence is identical in EphB1, EphB2, EphB3 an EphB4
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 100-115 kDa.
Related Product 1: EphB2-BKCD blocking peptide
Related Product 2: EphB1-pY594 phosphosite-specific antibody (Cat. No.: AB-PK609)
Related Product 3: EphB2-PCT pan-specific antibody (Cat. No.: AB-NK267-2)
Related Product 4: EphB2-pY780 phosphosite-specific antibody (Cat. No.: AB-PK610)
Related Product 5: EphB3-pY600 phosphosite-specific antibody (Cat. No.: AB-PK611)
Related Product 6: EphSubtide - EphB1 protein kinase substrate peptide
Related Product 1: EphB2-BKCD blocking peptide
Related Product 2: EphB1-pY594 phosphosite-specific antibody (Cat. No.: AB-PK609)
Related Product 3: EphB2-PCT pan-specific antibody (Cat. No.: AB-NK267-2)
Related Product 4: EphB2-pY780 phosphosite-specific antibody (Cat. No.: AB-PK610)
Related Product 5: EphB3-pY600 phosphosite-specific antibody (Cat. No.: AB-PK611)
Related Product 6: EphSubtide - EphB1 protein kinase substrate peptide
Scientific Background: EphB2 is a protein-tyrosine kinase of the TK group and Eph family. It is a receptor kinase, and is activated by binding ephrin-B1, B2, or B3. Eph and Eph receptors are associated with nervous system development events, and lead to contact-dependent signalling through adjacent cells. Eph receptors are widely expressed in early development and rarely detected in adult tissues. EphB2 signalling has an important role in the development and structural organization of neurons. EphB2 is also involved in angiogenesis, palate development and inner ear development through endolymph production. EphB2 appears to be a tumour suppressor protein (TSP). The active form of the protein kinase normally acts to inhibit tumour cell proliferation. EphB2 mutations have been found in prostate cancer. Most prostate cancers are adenocarcinomas that derived from acini of the prostatic ducts. K1019X mutation was significantly more common in African American probands. Over-expression of EphB2 has been frequently detected in both well-differentiated adenocarcinomas (10 of 13) and poorly differentiated adenocarcinomas (9 of 14). EphB2 expression restricts the invasiveness of colorectal cancer cells into ephrin-B1 expressing cell populations, thus segregating cancer cells from normal cells.
© Kinexus Bioinformatics Corporation 2017